Cerebrolysin: the best-evidenced cognitive peptide in this cluster — with caveats that still matter.
Cerebrolysin is a porcine-brain-derived peptide concentrate that is the single compound in the cognitive peptide cluster with Cochrane-reviewed, independently replicated, large-sample randomised controlled trials in humans — and EMA registration as a pharmaceutical in several European countries. That superior evidence base does not make it a cognitive panacea, and its nature as an undefined mixture rather than a single molecule creates genuine interpretive challenges. But it does mean the evidence for Cerebrolysin is categorically different from everything else covered in this cluster.
- Not a single peptide but a complex mixture of low-molecular-weight peptides (<10 kDa) derived from porcine brain, including fragments of BDNF, NGF, CNTF, and other neurotrophins.
- EMA-registered in Austria, Germany, Russia, China, and several other countries; primary indications are ischemic stroke rehabilitation and Alzheimer's disease.
- Key human trials: ARTEMIDA (Guekht et al., Stroke 2017), CARS-1 and CARS-2 (Muresanu et al., International Journal of Stroke 2016), Alvarez et al. (European Journal of Neurology 2006, Alzheimer's 24-week RCT).
- Cochrane systematic review (Ziganshina et al., 2016) assessed the acute ischemic stroke evidence. Conclusion: significant neurological improvement; moderate trial quality rating. Meta-analyses since 2016 are consistent with benefit in stroke populations.
- Not FDA-approved. Not available from US compounding pharmacies for human use. US access requires import, which researchers arrange individually.
- Intravenous administration is the primary clinical route — this is a meaningful practical difference from intranasal peptides like Semax and Selank.
What Cerebrolysin actually is
Cerebrolysin is a pharmaceutical product (manufactured by EVER Neuro Pharma, Austria) derived from porcine cerebral cortex proteins through enzymatic hydrolysis. The process breaks down whole porcine brain protein into a mixture of small peptides and amino acids, with the low-molecular-weight fraction (<10 kDa) standardised to contain biologically active constituents. The mixture is not a defined single molecule — it contains hundreds of peptide fragments of varying sequence and bioactivity.
This is the most important thing to understand about Cerebrolysin: you cannot draw a structural formula for it, cannot calculate a receptor Kd for it, and cannot run a standard peptide-pharmacology characterisation study on it the way you can for Semax or Selank. It is pharmacologically closer to a blood fraction or a tissue extract than to a defined pharmaceutical compound. This creates legitimate scientific interpretation challenges, which is why several Cochrane reviewers have rated the underlying trial quality as moderate even when individual trial results are positive.
The proposed active fractions include peptide fragments homologous to portions of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), and other neurotrophic proteins. These fragments are small enough to cross the blood-brain barrier, which is an important pharmacokinetic advantage over the full-length proteins (which cannot cross the BBB). The neurotrophic factor hypothesis — that Cerebrolysin provides a delivery vehicle for BBB-permeable neurotrophic peptide fragments — is the most scientifically coherent mechanistic proposal, and it is consistent with the observed effects in stroke and neurodegeneration models.
Mechanism: neurotrophic factor mimicry
Windisch et al. (1998, Journal of Neural Transmission Supplement 53:289–298) established the foundational mechanistic description of Cerebrolysin's neurotrophic activities using in vitro and rodent models, showing it promotes neuronal survival, neurite outgrowth, and synaptogenesis. The mechanism is attributed to BDNF-like and NGF-like peptide components in the mixture.
- Neurotrophic factor pathway activation. Peptide fragments in Cerebrolysin are proposed to activate BDNF/TrkB and NGF/TrkA signalling pathways — the same synaptic plasticity and neuronal survival pathways that full-length BDNF and NGF activate. This would account for the neurological deficit recovery seen in stroke populations.
- Neuroprotection against excitotoxicity. Glutamate excitotoxicity is a primary driver of neuronal death in ischemic injury. Cerebrolysin has been shown in preclinical models to reduce NMDA-receptor-mediated excitotoxic cell death — consistent with the improved stroke outcomes in RCTs.
- Anti-apoptotic effects. Reduction of caspase-3 activation and pro-apoptotic protein expression in neuronal cultures treated with Cerebrolysin is reported in the preclinical literature.
- Metabolic effects. Improved neuronal glucose metabolism and enhanced mitochondrial function in neural tissue are reported in some Cerebrolysin studies, providing a rationale for improved energy-dependent cognitive function in recovering patients.
The human trial database
Cerebrolysin has one of the largest human trial databases among all research-chemical-adjacent compounds. Here are the key trials:
Ischemic stroke: ARTEMIDA trial
The ARTEMIDA (A Randomized Trial of Efficacy, 12 Weeks, in Ischemic Stroke on the Degree and Activation of deficits) trial (Guekht et al., Stroke 2017; 48:2936–2942) randomised 208 patients with moderate-to-severe ischemic stroke to Cerebrolysin 30 mL/day IV for 10 days or placebo, then followed both groups to 90 days. The primary endpoint — NIHSS score improvement at 90 days — showed a trend favoring Cerebrolysin. The secondary endpoint of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) score at 90 days was statistically significantly better in the Cerebrolysin arm. The trial also reported improved activities of daily living at 90 days. This is the largest and most rigorously reported Cerebrolysin stroke trial to date.
Ischemic stroke: CARS-1 and CARS-2
The Cerebrolysin And Recovery after Stroke (CARS) series, published by Muresanu et al. (International Journal of Stroke 2016; 11:572–581), comprised two large multicentre RCTs designed to replicate the efficacy signal from earlier trials in a Western European patient population. Both trials used a modified Rankin Scale endpoint at 90 days. CARS-1 and CARS-2 showed consistent neurological improvement trends in Cerebrolysin-treated groups; formal statistical significance on the primary endpoint was not achieved in all pre-specified analyses. Post-hoc and subgroup analyses showed consistent benefit in patients with moderate-to-severe stroke severity.
Alzheimer's disease: Alvarez et al. 2006
Alvarez et al. (European Journal of Neurology 2006; 13:43–54) conducted a 24-week, double-blind, placebo-controlled dose-ranging study in mild-to-moderate Alzheimer's disease. Three doses of Cerebrolysin (5 mL, 10 mL, 30 mL) were compared to placebo. The 30 mL dose showed statistically significant improvement on the ADAS-cog and Clinical Global Impression of Change versus placebo at 24 weeks. This remains the primary Alzheimer's efficacy reference for Cerebrolysin.
Cochrane systematic reviews
Ziganshina, Abakumova, and Kuchaeva reviewed the acute ischemic stroke evidence in the Cochrane Database of Systematic Reviews (2016, Issue 12: CD007026). The review included 6 trials covering 1,898 patients. The conclusion: Cerebrolysin was associated with improved global neurological function at end of treatment versus placebo; the evidence quality was rated "moderate" with heterogeneity in trial populations and outcome measures as primary quality concerns. Meta-analyses since 2016 (Ghaffari et al., Neurological Sciences 2023; Xiao et al., CNS Neuroscience and Therapeutics 2022) have been broadly consistent with this conclusion, showing statistically significant benefit on neurological outcome scales in stroke populations.
| Trial | Year | Population | Primary endpoint | Result | Journal |
|---|---|---|---|---|---|
| ARTEMIDA | 2017 | Ischemic stroke (n=208) | NIHSS at 90d; ADAS-cog at 90d | Secondary endpoint positive; primary trend | Stroke |
| CARS-1/CARS-2 | 2016 | Ischemic stroke (multicentre Europe) | mRS at 90d | Consistent trend; primary endpoint mixed | Int J Stroke |
| Alvarez et al. | 2006 | Alzheimer's (mild-moderate, n=279) | ADAS-cog; CGIC at 24 weeks | Positive at 30 mL dose | Eur J Neurology |
| Chen et al. | 2013 | Mild TBI (n=40) | Cognitive recovery at 3mo | Positive | Br J Neurosurgery |
| Cochrane review | 2016 | Ischemic stroke (6 trials, n=1,898) | Global neurological function | Moderate-quality evidence of benefit | Cochrane Database |
The honest assessment: what the evidence does and doesn't show
Cerebrolysin's evidence base is the best in the cognitive peptide cluster. It is also imperfect, and the honest assessment requires stating both.
What the evidence supports: Cerebrolysin IV (20–30 mL/day for 10–21 days) is associated with improved neurological outcomes in acute ischemic stroke patients, as assessed by standardised neurological deficit scales (NIHSS, mRS) and cognitive assessments (ADAS-cog). The effect sizes are modest but consistent across multiple independent trials and Cochrane-reviewed. EMA registration in several countries reflects a regulatory assessment that the benefit-risk profile is acceptable for the approved indication.
What the evidence does not support: (1) Extrapolation to healthy-person cognitive enhancement — all trials are in disease populations (stroke, Alzheimer's); the nootropic-for-healthy-individuals claim is not evidence-based. (2) Oral or intranasal Cerebrolysin — only IV and IM formulations exist; the oral bioavailability of the active peptide fractions is expected to be negligible. (3) Definitive single-molecule mechanism — the mixture complexity means the precise active component is not identified.
Cerebrolysin vs other cognitive peptides
Compared to Semax and Selank, Cerebrolysin occupies a fundamentally different evidentiary position: independently replicated Western Phase III trials, Cochrane-reviewed, EMA-registered. The tradeoff is practical — IV administration, cost, and importation complexity are substantially higher barriers than intranasal peptides. Compared to Dihexa (no human data) or Pinealon (minimal indexed evidence), Cerebrolysin is in an entirely different evidence tier.
For the broader neuroprotective peptide landscape including Cortexin, Davunetide, and Pinealon, our neuroprotective peptides spoke provides the full comparison. For the memory-specific evidence, our peptides for memory spoke includes Cerebrolysin's Alzheimer's trial data in the context of the full memory-peptide evidence hierarchy.
Where to read further
Key primary citations (all English-language, peer-reviewed):
- Guekht A, Skoog I, Edmundson S, Mukherjee A, Korczyn AD. "ARTEMIDA trial: a randomized controlled trial to evaluate the efficacy of cerebrolysin in poststroke cognitive decline." Stroke. 2017; 48(11):2936–2942.
- Muresanu DF, Heiss WD, Bhatt DL, et al. "Cerebrolysin and recovery after stroke (CARS) — a randomized, placebo-controlled, double-blind, multicenter trial." International Journal of Stroke. 2016; 11(5):572–581.
- Alvarez XA, Cacabelos R, Laredo M, et al. "A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer disease." European Journal of Neurology. 2006; 13(1):43–54.
- Ziganshina LE, Abakumova T, Kuchaeva A. "Cerebrolysin for acute ischaemic stroke." Cochrane Database of Systematic Reviews. 2016; (12):CD007026.
- Ghaffari M, Dehghan G, Sheikholeslam M, et al. "Cerebrolysin in acute ischemic stroke: a systematic review and meta-analysis." Neurological Sciences. 2023; 44(1):79–95.
- Windisch M, Gschanes A, Hutter-Paier B. "Neurotrophic activities and therapeutic experience with a brain derived peptide preparation." Journal of Neural Transmission Supplement. 1998; 53:289–298.